Literature DB >> 11579649

A comparative trial of single dose chemotherapy in paucibacillary leprosy patients with two to three skin lesions.

.   

Abstract

A multicentric, double-blind, controlled, clinical trial was carried out to compare the efficacy of a combination of rifampicin 600 mg plus ofloxacin 400 mg plus minocycline 100 mg (ROM) administered as single dose with that of standard WHO/MDT/PB six months regimen. The study subjects were 236 previously untreated, smear-negative patients, without nerve trunk involvement and having only two or three skin lesions. Randomization was done on individual patient basis. Results were analyzed for mean clinical score for improvement, marked clinical improvement and complete clinical cure at the time of release from treatment and at 12 months and 18 months of follow-up. Clinical improvement was seen in most patients in both regimens. Marked improvement (i.e., more than 90% reduction in clinical score) at 18 months was seen in 46.2% and 53.4% of the patients treated with ROM and standard regimens, respectively. But, significant difference in favour of standard PB regimen was seen in patients with three skin lesions and in patients in whom more than one body part was affected. Reversal reaction and adverse drug reactions were minimal in both groups.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579649

Source DB:  PubMed          Journal:  Indian J Lepr        ISSN: 0254-9395


  2 in total

1.  Clinical and Histopathological Response to Multidrug Therapy in Paucibacillary Leprosy at the end of 6 Months: A Prospective Observational Study from Eastern India.

Authors:  Indrashis Podder; Abanti Saha; Debabrata Bandyopadhyay
Journal:  Indian J Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.494

2.  World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis.

Authors:  Maria Lazo-Porras; Gabriela J Prutsky; Patricia Barrionuevo; Jose Carlos Tapia; Cesar Ugarte-Gil; Oscar J Ponce; Ana Acuña-Villaorduña; Juan Pablo Domecq; Celso De la Cruz-Luque; Larry J Prokop; Germán Málaga
Journal:  BMC Infect Dis       Date:  2020-01-20       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.